Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 4, 2010, Pages 1046-1052

  Nguyen, Paul L ^a,d   Chen, Ming Hui ^b   Beard, Clair J ^a,d   Suh, W Warren ^a,d   Renshaw, Andrew A ^c   Loffredo, Marian ^a   McMahon, Elizabeth ^a   Kantoff, Philip W ^a,d   D'Amico, Anthony V ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c BAPTIST HOSPITAL OF MIAMI   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen suppression therapy; Comorbidity; High risk; Intermediate risk; Prostate cancer; Radiation; Randomized trial; Risk groups

Indexed keywords

ANDROGEN SUPPRESSION; ANDROGEN SUPPRESSION THERAPY; COMORBIDITY; HIGH RISK; INTERMEDIATE RISK; PROSTATE CANCERS; RANDOMIZED TRIAL;

DISEASES; EPIDEMIOLOGY; PESTICIDE EFFECTS; RADIOTHERAPY; RISK ANALYSIS;

RISK ASSESSMENT;

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; DEATH; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RANDOMIZATION; SCORING SYSTEM; SURVIVAL TIME; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 77951268845     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.038     Document Type: Article

References (18)

1. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
2. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
3. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
4. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
5. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
6. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
7. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
8. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 (2004) 2441-2447
9. Cox D.R. Regression models and life-tables. J Roy Statistical Society (Methodological) 34 (1972) 187-220
10. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
11. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
12. Zietman A.L. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 299 (2008) 898-899
13. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
14. Liauw S.L., Fricano J., Correa D., et al. Dose-escalated radiation therapy for intermediate-risk prostate cancer: Patient selection for androgen deprivation therapy using percentage of positive cores. Cancer 115 (2009) 1784-1790
15. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
16. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27 (2009) 92-99
17. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
18. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 113 (2008) 3290-3297